Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
5 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Loco-regional treatment for castration-resistant prostate cancer: Is there any rationale? A critical review from the AFU-GETUG.
Crit Rev Oncol Hematol. 2018 Feb;122:144-149. doi: 10.1016/j.critrevonc.2017.12.012. Epub 2017 Dec 30.
Crit Rev Oncol Hematol. 2018.
PMID: 29458782
Review.
Non-clear cell renal carcinomas: Review of new molecular insights and recent clinical data.
Barthélémy P, Rioux-Leclercq N, Thibault C, Saldana C, Borchiellini D, Chevreau C, Desmoulins I, Gobert A, Hilgers W, Khalil A, Lemoine N, Schlürmann-Constans F, Négrier S.
Barthélémy P, et al. Among authors: schlurmann constans f.
Cancer Treat Rev. 2021 Jun;97:102191. doi: 10.1016/j.ctrv.2021.102191. Epub 2021 Apr 9.
Cancer Treat Rev. 2021.
PMID: 34015728
Free article.
Review.
Item in Clipboard
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.
Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, Ferreira U, Efstathiou E, Madziarska K, Kolinsky MP, Cubero DIG, Noerby B, Zohren F, Lin X, Modelska K, Sugg J, Steinberg J, Hussain M; PROSPER Investigators.
Sternberg CN, et al.
N Engl J Med. 2020 Jun 4;382(23):2197-2206. doi: 10.1056/NEJMoa2003892. Epub 2020 May 29.
N Engl J Med. 2020.
PMID: 32469184
Clinical Trial.
Item in Clipboard
Targeted and immune therapies among patients with metastatic renal carcinoma undergoing hemodialysis: A systemic review.
Klajer E, Garnier L, Goujon M, Schlurmann-Constans F, Mery B, Nguyen Tan Hon T, Mouillet G, Calcagno F, Thiery-Vuillemin A.
Klajer E, et al. Among authors: schlurmann constans f.
Semin Oncol. 2020 Apr-Jun;47(2-3):103-116. doi: 10.1053/j.seminoncol.2020.05.001. Epub 2020 May 26.
Semin Oncol. 2020.
PMID: 32522380
Item in Clipboard
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.
Siefker-Radtke AO, Matsubara N, Park SH, Huddart RA, Burgess EF, Özgüroğlu M, Valderrama BP, Laguerre B, Basso U, Triantos S, Akapame S, Kean Y, Deprince K, Mukhopadhyay S, Loriot Y; THOR cohort 2 investigators.
Siefker-Radtke AO, et al.
Ann Oncol. 2024 Jan;35(1):107-117. doi: 10.1016/j.annonc.2023.10.003. Epub 2023 Oct 21.
Ann Oncol. 2024.
PMID: 37871702
Clinical Trial.
Item in Clipboard
Cite
Cite